The current global guideline recommendations for postnatal antiretroviral prophylaxis in vertical HIV transmission are discussed in this interview with Dr Martina Penazzato (World Health Organization (WHO), Geneva, Switzerland). Dr Penazzato also discusses new strategies currently under investigation to reduce HIV transmission, and the challenges that still remain in translating developments in HIV transmission to a paediatric setting.
The talk entitled: ‘Antiretrovirals for prevention: from adults to babies’ was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- Postnatal antiretroviral prophylaxis (PNP) is important for preventing vertical HIV transmission – what are the current global guideline recommendations for PNP? (0:32)
- What challenges have there been in implementing guideline recommendations? (2:32)
- Please outline what new strategies are currently under investigation to reduce HIV transmission? (4:58)
- What challenges remain in translating developments in HIV transmission to a paediatric setting, and how can these be overcome? (7:58)
- What impact would decreasing vertical HIV transmission have on patients and society at large? (10:11)
Disclosures: Martina Penazzato has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!